Edition:
United States

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

2.86USD
12:49pm EST
Change (% chg)

$0.10 (+3.62%)
Prev Close
$2.76
Open
$2.79
Day's High
$2.86
Day's Low
$2.79
Volume
4,402
Avg. Vol
31,326
52-wk High
$7.39
52-wk Low
$1.90

KOOL.OQ

Chart for KOOL.OQ

About

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and... (more)

Overall

Beta: -0.64
Market Cap(Mil.): $27.02
Shares Outstanding(Mil.): 9.79
Dividend: --
Yield (%): --

Financials

  KOOL.OQ Industry Sector
P/E (TTM): -- 29.51 30.38
EPS (TTM): -9.24 -- --
ROI: -85.27 15.44 14.86
ROE: -109.75 16.62 16.28

BRIEF-Cesca Therapeutics files for resale of up to 950,000 common shares

* Files for resale of up to 950,000 shares of co's common stock by the selling stockholders - sec filing

Jan 20 2017

BRIEF-Cesca Therapeutics says on Jan 10, board increased its size to six members - SEC filing

* Cesca Therapeutics Inc- On January 10, 2017, board of directors of Cesca Therapeutics Inc increased size of its board to six members - SEC filing Source text : (http://bit.ly/2iynEWx) Further company coverage:

Jan 17 2017

BRIEF-Cesca Therapeutics files for a non-timely 10-Q

* Cesca Therapeutics - files for a non-timely 10-Q - SEC filing

Nov 10 2016

BRIEF-Cesca Therapeutics granted third U.S. patent relating to its proprietary SurgWerks Platform

* Cesca Therapeutics Inc - Cesca Therapeutics granted third U.S. patent relating to its proprietary SurgWerks platform Source text for Eikon: Further company coverage:

Oct 18 2016

BRIEF-Cesca Therapeutics receives patents for infusion of bone marrow derived stem cells

* Cesca Therapeutics granted two patents for rapid infusion of autologous bone marrow derived stem cells Source text for Eikon: Further company coverage:

Sep 19 2016

BRIEF-Cesca therapeutics to report fiscal Q4 and FY2016 financial results

* Cesca therapeutics to report fiscal fourth quarter and full year 2016 financial results and provide business update Source text for Eikon: Further company coverage:

Sep 16 2016

BRIEF-Cesca Therapeutics to convert $12.5 mln in senior secured debt to equity

* Cesca Therapeutics announces conversion of $12.5 million in senior secured debt to equity

Aug 24 2016

BRIEF-Empery Asset Management LP reports 5.43 pct passive stake in Cesca Therapeutics

* Empery Asset Management, LP reports 5.43 pct passive stake in Cesca Therapeutics as of August 4, 2016 - SEC Filing Source - http://bit.ly/2bl8rAM Further company coverage:

Aug 15 2016

BRIEF-Cesca Therapeutics announces pricing of $2.5 mln registered direct offering

* Cesca Therapeutics announces pricing of $2.5 million registered direct offering

Aug 04 2016

BRIEF-Cesca Therapeutics provides update on FDA review of Surgwerks CLI pivotal trial

* Cesca Therapeutics provides update on FDA review of investigational device exemption supplement for Surgwerks CLI pivotal trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

Aug 01 2016

Earnings vs. Estimates